Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e102-e105. doi: 10.1111/jdv.19457. Epub 2023 Aug 31.

Authors

C A Rubio-Muniz¹, A Sánchez-Velázquez¹, J Arroyo-Andrés¹, M Agud-de Dios¹, E J Tarín-Vicente¹, D Falkenhain-López¹, P L Ortiz-Romero^{1

2}

Affiliations

¹ Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
² Institute i+12 CIBERONC, Medical School, University Complutense, Madrid, Spain.

PMID: 37611255
DOI: 10.1111/jdv.19457

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Humans
Mycosis Fungoides* / drug therapy
Photopheresis*
Sezary Syndrome* / drug therapy
Skin Neoplasms* / drug therapy

Substances

mogamulizumab